Matthew Gombrich, M.D., M.S. - President/Founder
The founder of Viridis Bioscience is Dr. Matthew Gombrich. Dr. Gombrich has an extensive history in the point-of-care diagnsotic arena. Prior to establishing Viridis, Dr. Gombrich was Director of Clinical Research for Inverness Medical (through their Binax acquisition). Dr. Gombrich was involved with the evolution of Binax's Legionella and Pneumococcal urinary antigen tests in the clinical arena.
Prior to Dr. Gombrich's matriculation at Case Western Reserve School of Medicine, where he also received a Master of Science degree in Experimental Pathology, he was Chief Scientist at Molecular Diagnostics, a bioscience diagnostic company aimed at developing a novel method of cervical cancer detection.
John Evans, Ph.D. - Founder
John
N. Evans, Ph.D. is a Professor of physiology and biophysics at the University
of Vermont College of Medicine. Dr. Evans formerly served with distinction as
the 16th Dean of the College of Medicine. Dr. Evans conceptualized and
completed the construction of the $30 million Health Science Research Facility,
and established a technology transfer process for the College that has resulted
in increased patents and licensing agreements. Along with former Dean John
Frymoyer, M.D., Evans also initiated the effort to redesign the medical
curriculum that was launched in Fall 2003. External funding for research more
than tripled between 1992 and 2003. As Senior Advisor to the President, Evans
played a significant role in the acquisition of the Trinity College campus, led
planning for the high technology incubator, and developed a strategic
partnership with the State for a joint research facility. Dr. Evans has published extensively on
lung disease and served on the Editorial Board of several journals, including
Pulmonary Pharmacology, American Review of Respiratory Diseases, and American
Journal of Physiology. He is also a reviewer for the journals Lung,
Experimental Lung Research, Journal of Pharmacology and Experimental
Therapeutics, and American Journal of Physiology. A founding member of the
Vermont Technology Council, Evans has served on the Board since 1992, and is
also an active member of the Greater Burlington Industrial Corporation. He
serves on the Board of Trustees for Fletcher Allen Health Care, the College’s
partner in Vermont’s only academic health center.
Paul Haley, Ph.D. - VP, Assay Development
Dr. Haley has over 25 years experience in the field of protein biochemistry with particular emphasis in the areas of enzymology, membrane biochemistry, and immunochemistry, working with systems ranging from photosynthetic bacteria to mammalian blood coagulation. He has extensive experience in reagent formulation for IVD as well as in stabilizing and preparing biological specimens for subsequent bioassay. As co-founder and Scientific Director at Research Proteins, Inc. (a contract R&D company), he has developed chemistries for over 100 different companies in the IVD arena. Previously, as Director of Product Development at Haematologic Technologies Inc, he was responsible for establishing and overseeing all aspects of the reagent manufacturing business which involved the development and implementation of protocols for the isolation, characterization and formulation of over 50 different proteins from a variety of human and animal sources. Dr. Haley has also directed the development of reagent and control formulations for several POC coagulation monitors as well as a line of specialty blood collection tubes. His familiarity with cGMP practices and the FDA 510(k) clearance process are assets to this project.
Todd Keiller - Advisor, Business Development
Mr. Keiller currently serves as Director of UVM Ventures. Prior to this position Mr. Keiller held the position of VP at Bringham and Women's Hospital in Boston. Mr. Keiller also was a former Marketing Manager at Corning Medical.
Viridis Bioscience prides itself on its strong strategic partners. Representing both exceptional reagent development and engineering, Viridis is working with leaders in the immunologic development field as well a leader in fluidic engineering platform development and production to bring the Viridis disposable hand-held system to market. Our goal...bring extremely sensitive, rapid testing to the severe infectious disease arena to provide physicians the information necessary for prudent therapy.